DK2094703T3 - Nikotiniske acetylcholin-receptorsubtype-selektive amider af diazabicycloalkaner - Google Patents

Nikotiniske acetylcholin-receptorsubtype-selektive amider af diazabicycloalkaner

Info

Publication number
DK2094703T3
DK2094703T3 DK07863786.5T DK07863786T DK2094703T3 DK 2094703 T3 DK2094703 T3 DK 2094703T3 DK 07863786 T DK07863786 T DK 07863786T DK 2094703 T3 DK2094703 T3 DK 2094703T3
Authority
DK
Denmark
Prior art keywords
diazabicycloalkanes
acetylcholine receptor
nicotinic acetylcholine
receptor subtype
subtype selective
Prior art date
Application number
DK07863786.5T
Other languages
Danish (da)
English (en)
Inventor
Anatoly Mazurov
Lan Miao
Yun-De Xiao
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK2094703T3 publication Critical patent/DK2094703T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK07863786.5T 2006-11-02 2007-11-01 Nikotiniske acetylcholin-receptorsubtype-selektive amider af diazabicycloalkaner DK2094703T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
DK2094703T3 true DK2094703T3 (da) 2011-08-29

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07863786.5T DK2094703T3 (da) 2006-11-02 2007-11-01 Nikotiniske acetylcholin-receptorsubtype-selektive amider af diazabicycloalkaner

Country Status (32)

Country Link
US (6) US8114889B2 (enExample)
EP (2) EP2284171B1 (enExample)
JP (2) JP5539723B2 (enExample)
KR (2) KR20100124356A (enExample)
CN (4) CN101528745B (enExample)
AR (2) AR063451A1 (enExample)
AT (2) ATE509022T1 (enExample)
AU (2) AU2007317433B2 (enExample)
BR (2) BRPI0722387A2 (enExample)
CA (1) CA2663925C (enExample)
CL (1) CL2007003155A1 (enExample)
CO (1) CO6180435A2 (enExample)
CY (1) CY1112374T1 (enExample)
DK (1) DK2094703T3 (enExample)
ES (2) ES2395212T3 (enExample)
HR (1) HRP20110570T1 (enExample)
IL (2) IL197618A (enExample)
MX (1) MX2009004801A (enExample)
MY (2) MY145602A (enExample)
NO (1) NO20091251L (enExample)
NZ (2) NZ587847A (enExample)
PE (2) PE20081441A1 (enExample)
PL (1) PL2094703T3 (enExample)
PT (1) PT2094703E (enExample)
RS (1) RS51834B (enExample)
RU (2) RU2448969C2 (enExample)
SA (1) SA07280584B1 (enExample)
SI (1) SI2094703T1 (enExample)
TW (3) TWI454262B (enExample)
UA (2) UA106718C2 (enExample)
UY (1) UY30686A1 (enExample)
WO (1) WO2008057938A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
CA2716863A1 (en) * 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
JP2012502039A (ja) * 2008-09-05 2012-01-26 ターガセプト，インコーポレイテッド ジアザビシクロオクタンのアミド及びその用途
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
CA2759476C (en) 2009-04-30 2018-10-09 Julie Nicole Hamblin Novel compounds
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
PL2513085T3 (pl) 2009-11-18 2017-09-29 Suven Life Sciences Limited Związki dwupierścieniowe jako ligandy receptora nikotynowego alfa4beta2 acetylocholiny
MX2012006909A (es) 2009-12-29 2012-07-10 Suven Life Sciences Ltd LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
WO2015078803A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
IL293188B2 (en) 2014-10-20 2025-06-01 Oyster Point Pharma Inc The compound varenicline for use as a medicament for treating dry eye, increasing tear production and treating ocular discomfort, and a pharmaceutical formulation comprising varenicline
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
EP3353178B1 (en) * 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
PE20180461A1 (es) 2015-09-24 2018-03-06 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de la atx
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
US10709707B2 (en) 2016-04-07 2020-07-14 Oyster Point Pharma, Inc. Methods of treating ocular conditions
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) * 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) * 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
ATE289607T1 (de) * 1999-12-14 2005-03-15 Neurosearch As Neue heteroaryl-diazabizykloalkane
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
EP1406900B1 (en) * 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
MXPA05006861A (es) * 2003-02-27 2005-12-12 Neurosearch As Derivados arildiazabiciclicos novedosos.
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
BRPI0511982A (pt) * 2004-06-09 2008-01-22 Hoffmann La Roche compostos antiviróticos heterocìclicos
EP1781670A1 (en) 2004-07-22 2007-05-09 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
RU2007146444A (ru) * 2005-05-13 2009-06-20 Лексикон Фармасьютикалз, Инк. (Us) Полициклические соединения и способы их применения
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
RU2009120674A (ru) 2010-12-10
UY30686A1 (es) 2009-08-03
HRP20110570T1 (hr) 2011-09-30
MY156730A (en) 2016-03-15
CL2007003155A1 (es) 2008-05-16
EP2094703A1 (en) 2009-09-02
TWI454262B (zh) 2014-10-01
US8268860B2 (en) 2012-09-18
WO2008057938A1 (en) 2008-05-15
CN102942569B (zh) 2015-10-28
AU2010219323A1 (en) 2010-09-30
ATE509022T1 (de) 2011-05-15
CN102020646B (zh) 2013-11-13
CN102838605A (zh) 2012-12-26
PT2094703E (pt) 2011-07-22
IL209026A (en) 2014-03-31
JP2013056919A (ja) 2013-03-28
TW200826935A (en) 2008-07-01
US20120289572A1 (en) 2012-11-15
UA98944C2 (ru) 2012-07-10
BRPI0722387A2 (pt) 2023-02-23
IL197618A (en) 2013-09-30
AR079840A2 (es) 2012-02-22
HK1149751A1 (en) 2011-10-14
US20150080576A1 (en) 2015-03-19
RU2517693C2 (ru) 2014-05-27
CA2663925A1 (en) 2008-05-15
US8921410B2 (en) 2014-12-30
KR20090074051A (ko) 2009-07-03
UA106718C2 (uk) 2014-10-10
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
US20160039833A1 (en) 2016-02-11
CN102838605B (zh) 2017-04-26
JP2010509230A (ja) 2010-03-25
SA07280584B1 (ar) 2010-11-02
US20100081683A1 (en) 2010-04-01
NZ575557A (en) 2011-01-28
ATE545646T1 (de) 2012-03-15
MX2009004801A (es) 2009-07-31
AU2007317433A1 (en) 2008-05-15
CO6180435A2 (es) 2010-07-19
AR063451A1 (es) 2009-01-28
US20100173932A1 (en) 2010-07-08
TWI405763B (zh) 2013-08-21
RU2009138600A (ru) 2011-04-27
TW201305176A (zh) 2013-02-01
ES2395212T3 (es) 2013-02-11
CA2663925C (en) 2015-04-21
BRPI0717930A2 (pt) 2011-05-10
US8859609B2 (en) 2014-10-14
MY145602A (en) 2012-03-15
US9580434B2 (en) 2017-02-28
JP5539723B2 (ja) 2014-07-02
CN102020646A (zh) 2011-04-20
KR101415705B1 (ko) 2014-07-04
EP2094703B1 (en) 2011-05-11
IL197618A0 (en) 2009-12-24
HK1133260A1 (en) 2010-03-19
AU2007317433B2 (en) 2012-05-10
US20130005789A1 (en) 2013-01-03
PE20110671A1 (es) 2011-10-20
ES2395157T3 (es) 2013-02-08
RU2448969C2 (ru) 2012-04-27
EP2284171A1 (en) 2011-02-16
NZ587847A (en) 2011-09-30
PL2094703T3 (pl) 2011-10-31
TW201114424A (en) 2011-05-01
JP5739398B2 (ja) 2015-06-24
SI2094703T1 (sl) 2011-07-29
CN101528745B (zh) 2011-09-14
EP2284171B1 (en) 2012-02-15
TWI404532B (zh) 2013-08-11
KR20100124356A (ko) 2010-11-26
IL209026A0 (en) 2011-01-31
NO20091251L (no) 2009-05-28
PE20081441A1 (es) 2008-10-30
CN102942569A (zh) 2013-02-27
CY1112374T1 (el) 2015-12-09
RS51834B (sr) 2012-02-29
US8114889B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
DK2094703T3 (da) Nikotiniske acetylcholin-receptorsubtype-selektive amider af diazabicycloalkaner
DK2089364T3 (da) Pyridinonforbindelser
DK2170864T3 (da) Pyridon-GPR119-G-protein-koblede receptoragonister
DK2081951T3 (da) Progesteron-receptorantagonister
DK2049506T4 (da) Modulatorer af farmakokinetiske egenskaber af terapeutik
DK2129654T3 (da) Antagonister af glucagonreceptoren
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
EP2079307A4 (en) Farnesoid X RECEPTOR AGONISTS
DK2049478T3 (da) Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf
DE602007006535D1 (de) Diazepan-acetamidderivate als selektive 11-hsd1-hemmer
NO347644B1 (no) Polymorfer
DE602007010456D1 (de) Phenyl-pyrazol-derivate als nicht-steroide glucocorticoid-rezeptorliganden
DK2024556T3 (da) Indretning til fremføring af stofstykker
BRPI0810926A2 (pt) Antagonista de crig
DK2029567T3 (da) Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
DK2305263T3 (da) Stabiliserede amorfe former af imatinibmesylat
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
BRPI0815006A2 (pt) Recuperação de salmoura de formiato
EP2087842A4 (en) IMAGING DEVICE
ATE534628T1 (de) Urotensin ii-rezeptorantagonisten
BRPI0808029A2 (pt) Derivados de azabicicloalcano de subtipo seletivo
DE112007003149A5 (de) Spannfutter
BRPI0812773A2 (pt) Antagonista do receptor de urotensina ii